IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: S. V. Govindan, et al.

Title: STABLE RADIOIODINE CONJUGATES AND METHODS FOR THEIR

SYNTHESIS

Appl. No.: Unassigned

Filing Date: 10/15/2003

Examiner: Unknown

Art Unit: Unknown

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 08/919,477; 09/696,740, filed 08/28/1997; 10/26/2000. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Oct. 16, 2003

FOLEY & LARDNER

Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399

Stephen B. Maebius Attorney for Applicant Registration No. 35,264

John B Mach

Page 1 of 4

Form PTO-14	49	U.S. DEPARTME	NT OF COMMERCE		ATTY. DOCKET NO.		SERIAL NO.			
(MODIFIED)		PATENT AND TR	ADEMARK OFFICE		018733/1	292	Unassigned			
INFORMATION DISCLOSURE CITATION					APPLICANT					
INFC				-	DI DIG 5 : T-	S. V. Govind		D.I.D.V.		
(Use several sheets if necessary)					FILING DATE		GROUP AR			
	Subm	itted on: February 26	, 2001		Unkno	w 	Ü	Inknown		
	-		U.S. PATI	ENT	DOCUMENTS					
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	CLASS		NG DATE IF OPRIATE	
	Al	5,274,076	12/28/1993 B	Barbe	et et al.	530	330			
	A2	5,273,738	12/28/1993 N	/latth	news et al.	424	1.1		•	
-	 									
			<u> </u>							
	.1,		FOREIGN PA	ATI	ENT DOCUMENTS		<u> </u>			
	Γ.	DOCUMENT					SUB-	TRANS	LATION	
	REF	NUMBER DATE		COUNTRY		CLASS	CLASS	YES	NO	
	A3	0 419 387	03/27/1991 E	urop	pe				ABST.	
	A4	0 492 478	07/01/1992 E	Europe						
	A5	2 109 407	06/2/1983 U	United Kingdom						
•										
		OTHER DOC	CUMENTS (Includi	ng A	Author, Title, Date, P	ertinent Pages, I	Etc.)			
					OTYROSINE DESIOD			ROIDIEN	SET	
	A6				<i>ta, 293</i> , pp. 36-47, (197					
					Monoclonal Antibodic					
	A7				<u>er Research 55</u> , pp. 313					
	-									
	A8	-	DEVYS, Anne et al., XP-002054227, "Comparative targeting of human colon-cancinoma multicell spheroids using one- and two-step (bispecific antibody) techniques", <i>Int. J. Cancer</i> , 67(6), 2 sheets, (1996), United 211 INSERM							
		-			ical Abstracts, Vol. 109				· 	
	A9	Diritioni, i aui C.,	. Thanhacology, <u>cr</u>			, pp. 1 and			_	
	 	STRORFI Jaffrey	Let al "125 L-Glycoco	nine	age Lahels for Identify	ng Sites of Protein	Catabolism i	ı Vivo:		
	A 10	STROBEL, Jeffrey L. et al., "125I-Glycoconjugage Labels for Identifying Sites of Protein Catabolism in Vivo: Effect of Structure and Chemistry of Coupling to Protein on label Entrapment in Cells after Protein Degradation ¹ ",								
	A10	Archives of Biochemistry and Biophysics, Vol. 240, No. 2, pp. 635-645, (8/1/1985)								
EXAMINEI	<u> </u>	Archives of Blochem	usiry and biophysics,	r UI.	DATE CONSIDI	<u> </u>				
LAAMINE	N.				DATE CONSIDI	LRED				
* EXA	MINED	Initial if sitation	n considered what	than	or not citation is	in conformance	with MDE	P 600. D	raw line	
					ered. Include any o					
	icant.				v	- -				

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 018733/0905 09/696,740 APPLICANT INFORMATION DISCLOSURE CITATION S. V. Govindan, et al. (Use several sheets if necessary) FILING DATE **GROUP ART UNIT** Submitted on: February 26, 2001 October 26, 2000 1644 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) GOLDENBERG, David M., "Monoclonal Antibodies in Cancer Detection and Therapy", The American Journal of A11 Medicine, Vol. 94, pp. 297-312, (March 1993), Cahners Publishing Company FRANANO, F. Nicholas et al., "Metabolism of Receptor Targeted 111 In-DTPA-Glycoproteins: Identification of 111 In-DTPA-∈-lysine as the Primary Metabolic and Excretory Product", Nucl. Med. Biol., Vol. 21, No. 8, A12 pp. 1023-1034, (1994), Elseview Science Ltd. ALI, Seham A. et al., "Improving the Tumor Retention of Radioiodinated Antibody: Aryl Carbohydrate Adducts1", A13 Cancer Research (Suppl.) 50, pp. 783s-788s, (February 1, 1999) PAWLAK-BYCZKOWSKA, Elizabeth J. et al., "Two New Monoclonal Antibodies, EPB01 and EPB-2, Reactive A14 with Human Lymphoma¹", Cancer Research 49, pp. 4568-4577, (August 5, 1989) WILBUR, D. Scott et al., "Development of a Stable Radioiodinating Reagent to Label Monoclonal Antibodies for A15 Radiotherapy of Cancer", *The Journal of. Nuclear. Médicine*, 30, pp. 216-226, (1989) STEIN, Rhona et al., "Murine Monoclonal Antibodies Raised against Human Non-Small Carcinoma of the Lung: A16 Specificity and Tumor Targeting¹", Cancer Research 50, pp. 1330-1336, (February 15, 1990) GOVINDAN, Serengulam V. et al., "Thiolations, 99mTc Labelings, and Animal In Vivo Biodistributions of Divalent A17 Monoclonal Antibody Fragments^{†,}", Bioconjugate Chem. 7, pp. 290-297, (1996), American Chemical Society HANSEN, Hans J. et al., "Characterization of Second-Generation Monoclonal Antibodies Against Charinoembryonic A18 Antigen", CANCER Vol. 71, No. 11, pp. 3478-3485, (June 1, 1993), American Cancer Society

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

	Substitute for form	1449	В/РТО	Complete if Known			
	INFORMATION D	ISCLO	OSURE	Application Number	Unassigned		
	STATEMENT BY	APPL	.ICANT	Filing Date	10/15/2003		
	Date Submitted: Oc	tohor	15 2002	First Named Inventor	S. V. Govindan et al.		
	Date Submitted. Oc	ropei	15, 2005	Group Art Unit	Unassigned		
(use as many sheets	s as n	ecessary)	Examiner Name	Unassigned		
Sheet	3	of	3	Attorney Docket Number	018733-0905		

	U.S. PATENT DOCUMENTS								
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1			Kind Code⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	A19	wo	99/11294		IMMUNOMEDICS, INC.	03-11-1999			
	A20	wo	98/08548		IMMUNOMEDICS, INC.	03-05-1998			
								+	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A21	S.V. GOVINDAN et al., "Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid- Appended Radioiodinated Peptides Containing D-Amino Acids," Bioconjugate Chem. 1999, 10(2):231-240, American Chemical Society (XP-002202221).	
	A22	R.M. SHARKEY et al., "Advantage of residuallizing radiolabels for an Internallizing antibody against the B-cell lymphoma antigen, CD22," Cancer Immunol. Immunother. (1997) Vol. 44:179-188, Springer-Verlag (XP-002202223).	
	A23	L. SHIH et al., "Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice," Cancer Immunol. Immunother. (2000), 49:208-216, Springer-Verlag (XP-002202222).	
	A24	J.L. STROBEL et al., "I-Glycoconjugate Labes for Identifying Sites of Protein Catabolism in vivo: Effect of Structure and Chemistry of Coupling to Protein on Label Entrapment in Cells after Protein Degradation," Archives of Biochemistry and Biophysics (1985) 240(2):635-645, Academic Press Inc. (XP-001073950).	